108 related articles for article (PubMed ID: 24835785)
1. Structure-based efforts to optimize a non-β-lactam inhibitor of AmpC β-lactamase.
Hendershot JM; Mishra UJ; Smart RP; Schroeder W; Powers RA
Bioorg Med Chem; 2014 Jul; 22(13):3351-9. PubMed ID: 24835785
[TBL] [Abstract][Full Text] [Related]
2. Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
Weston GS; Blázquez J; Baquero F; Shoichet BK
J Med Chem; 1998 Nov; 41(23):4577-86. PubMed ID: 9804697
[TBL] [Abstract][Full Text] [Related]
3. Structure-based discovery of a novel, noncovalent inhibitor of AmpC beta-lactamase.
Powers RA; Morandi F; Shoichet BK
Structure; 2002 Jul; 10(7):1013-23. PubMed ID: 12121656
[TBL] [Abstract][Full Text] [Related]
4. Structure-based optimization of a non-beta-lactam lead results in inhibitors that do not up-regulate beta-lactamase expression in cell culture.
Tondi D; Morandi F; Bonnet R; Costi MP; Shoichet BK
J Am Chem Soc; 2005 Apr; 127(13):4632-9. PubMed ID: 15796528
[TBL] [Abstract][Full Text] [Related]
5. The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase.
Powers RA; Blázquez J; Weston GS; Morosini MI; Baquero F; Shoichet BK
Protein Sci; 1999 Nov; 8(11):2330-7. PubMed ID: 10595535
[TBL] [Abstract][Full Text] [Related]
6. 4-Substituted trinems as broad spectrum beta-lactamase inhibitors: structure-based design, synthesis, and biological activity.
Plantan I; Selic L; Mesar T; Anderluh PS; Oblak M; Prezelj A; Hesse L; Andrejasic M; Vilar M; Turk D; Kocijan A; Prevec T; Vilfan G; Kocjan D; Copar A; Urleb U; Solmajer T
J Med Chem; 2007 Aug; 50(17):4113-21. PubMed ID: 17665896
[TBL] [Abstract][Full Text] [Related]
7. Nanomolar inhibitors of AmpC beta-lactamase.
Morandi F; Caselli E; Morandi S; Focia PJ; Blázquez J; Shoichet BK; Prati F
J Am Chem Soc; 2003 Jan; 125(3):685-95. PubMed ID: 12526668
[TBL] [Abstract][Full Text] [Related]
8. Validation of the AmpC β-lactamase binding site and identification of inhibitors with novel scaffolds.
Chan FY; Neves MA; Sun N; Tsang MW; Leung YC; Chan TH; Abagyan R; Wong KY
J Chem Inf Model; 2012 May; 52(5):1367-75. PubMed ID: 22559726
[TBL] [Abstract][Full Text] [Related]
9. Structure-based approach for binding site identification on AmpC beta-lactamase.
Powers RA; Shoichet BK
J Med Chem; 2002 Jul; 45(15):3222-34. PubMed ID: 12109906
[TBL] [Abstract][Full Text] [Related]
10. Novel non-β-lactam inhibitor of β-lactamase TEM-171 based on acylated phenoxyaniline.
Grigorenko VG; Andreeva IP; Rubtsova MY; Deygen IM; Antipin RL; Majouga AG; Egorov AM; Beshnova DA; Kallio J; Hackenberg C; Lamzin VS
Biochimie; 2017 Jan; 132():45-53. PubMed ID: 27771370
[TBL] [Abstract][Full Text] [Related]
11. Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy.
Venturelli A; Tondi D; Cancian L; Morandi F; Cannazza G; Segatore B; Prati F; Amicosante G; Shoichet BK; Costi MP
J Med Chem; 2007 Nov; 50(23):5644-54. PubMed ID: 17956081
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design and in-parallel synthesis of inhibitors of AmpC beta-lactamase.
Tondi D; Powers RA; Caselli E; Negri MC; Blázquez J; Costi MP; Shoichet BK
Chem Biol; 2001 Jun; 8(6):593-611. PubMed ID: 11410378
[TBL] [Abstract][Full Text] [Related]
13. Toward better antibiotics: crystallographic studies of a novel class of DD-peptidase/beta-lactamase inhibitors.
Silvaggi NR; Kaur K; Adediran SA; Pratt RF; Kelly JA
Biochemistry; 2004 Jun; 43(22):7046-53. PubMed ID: 15170342
[TBL] [Abstract][Full Text] [Related]
14. Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
Buzzoni V; Blazquez J; Ferrari S; Calò S; Venturelli A; Costi MP
Bioorg Med Chem Lett; 2004 Aug; 14(15):3979-83. PubMed ID: 15225711
[TBL] [Abstract][Full Text] [Related]
15. Thermodynamic cycle analysis and inhibitor design against beta-lactamase.
Roth TA; Minasov G; Morandi S; Prati F; Shoichet BK
Biochemistry; 2003 Dec; 42(49):14483-91. PubMed ID: 14661960
[TBL] [Abstract][Full Text] [Related]
16. Three-dimensional structure of AmpC beta-lactamase from Escherichia coli bound to a transition-state analogue: possible implications for the oxyanion hypothesis and for inhibitor design.
Usher KC; Blaszczak LC; Weston GS; Shoichet BK; Remington SJ
Biochemistry; 1998 Nov; 37(46):16082-92. PubMed ID: 9819201
[TBL] [Abstract][Full Text] [Related]
17. Energetic, structural, and antimicrobial analyses of beta-lactam side chain recognition by beta-lactamases.
Caselli E; Powers RA; Blasczcak LC; Wu CY; Prati F; Shoichet BK
Chem Biol; 2001 Jan; 8(1):17-31. PubMed ID: 11182316
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum beta-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods.
Venkatesan AM; Agarwal A; Abe T; Ushirogochi H; Yamamura I; Ado M; Tsuyoshi T; Dos Santos O; Gu Y; Sum FW; Li Z; Francisco G; Lin YI; Petersen PJ; Yang Y; Kumagai T; Weiss WJ; Shlaes DM; Knox JR; Mansour TS
J Med Chem; 2006 Jul; 49(15):4623-37. PubMed ID: 16854068
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and structural analysis of inhibitors targeting the ADC-7 cephalosporinase of Acinetobacter baumannii.
Powers RA; Swanson HC; Taracila MA; Florek NW; Romagnoli C; Caselli E; Prati F; Bonomo RA; Wallar BJ
Biochemistry; 2014 Dec; 53(48):7670-9. PubMed ID: 25380506
[TBL] [Abstract][Full Text] [Related]
20. Functional analyses of AmpC beta-lactamase through differential stability.
Beadle BM; McGovern SL; Patera A; Shoichet BK
Protein Sci; 1999 Sep; 8(9):1816-24. PubMed ID: 10493583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
